| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Functional impact of global rare copy number variation in autism spectrum disorders.
|
Nature
|
2010
|
14.66
|
|
2
|
Autism genome-wide copy number variation reveals ubiquitin and neuronal genes.
|
Nature
|
2009
|
9.47
|
|
3
|
Risperidone in children with autism and serious behavioral problems.
|
N Engl J Med
|
2002
|
9.35
|
|
4
|
A genome-wide scan for common alleles affecting risk for autism.
|
Hum Mol Genet
|
2010
|
3.42
|
|
5
|
Individual common variants exert weak effects on the risk for autism spectrum disorderspi.
|
Hum Mol Genet
|
2012
|
2.46
|
|
6
|
Parent-rated anxiety symptoms in children with pervasive developmental disorders: frequency and association with core autism symptoms and cognitive functioning.
|
J Abnorm Child Psychol
|
2007
|
1.98
|
|
7
|
Risperidone and adaptive behavior in children with autism.
|
J Am Acad Child Adolesc Psychiatry
|
2006
|
1.71
|
|
8
|
Validity of the autism diagnostic interview-revised.
|
Am J Ment Retard
|
2006
|
1.66
|
|
9
|
Children's Yale-Brown Obsessive Compulsive Scale modified for pervasive developmental disorders.
|
J Am Acad Child Adolesc Psychiatry
|
2006
|
1.61
|
|
10
|
Increased prevalence of familial autoimmunity in probands with pervasive developmental disorders.
|
Pediatrics
|
2003
|
1.56
|
|
11
|
Medication and parent training in children with pervasive developmental disorders and serious behavior problems: results from a randomized clinical trial.
|
J Am Acad Child Adolesc Psychiatry
|
2009
|
1.55
|
|
12
|
Onset and exacerbation of obsessive-compulsive disorder in pregnancy and the postpartum period.
|
J Clin Psychiatry
|
2010
|
1.47
|
|
13
|
Gastrointestinal symptoms in a sample of children with pervasive developmental disorders.
|
J Autism Dev Disord
|
2008
|
1.46
|
|
14
|
A novel approach of homozygous haplotype sharing identifies candidate genes in autism spectrum disorder.
|
Hum Genet
|
2011
|
1.43
|
|
15
|
Cerebrospinal fluid corticotropin-releasing factor and perceived early-life stress in depressed patients and healthy control subjects.
|
Neuropsychopharmacology
|
2004
|
1.41
|
|
16
|
A pilot study of D-cycloserine in subjects with autistic disorder.
|
Am J Psychiatry
|
2004
|
1.40
|
|
17
|
Weight gain associated with atypical antipsychotic use in children and adolescents: prevalence, clinical relevance, and management.
|
Paediatr Drugs
|
2004
|
1.26
|
|
18
|
Acute and long-term safety and tolerability of risperidone in children with autism.
|
J Child Adolesc Psychopharmacol
|
2005
|
1.24
|
|
19
|
Structural and functional magnetic resonance imaging of autism spectrum disorders.
|
Brain Res
|
2010
|
1.22
|
|
20
|
A naturalistic retrospective analysis of psychostimulants in pervasive developmental disorders.
|
J Child Adolesc Psychopharmacol
|
2004
|
1.20
|
|
21
|
Atypical antipsychotics in the treatment of children and adolescents with pervasive developmental disorders.
|
Psychopharmacology (Berl)
|
2013
|
1.19
|
|
22
|
Effects of short- and long-term risperidone treatment on prolactin levels in children with autism.
|
Biol Psychiatry
|
2006
|
1.18
|
|
23
|
High nitric oxide production in autistic disorder: a possible role for interferon-gamma.
|
Biol Psychiatry
|
2004
|
1.18
|
|
24
|
A retrospective study of memantine in children and adolescents with pervasive developmental disorders.
|
Psychopharmacology (Berl)
|
2006
|
1.18
|
|
25
|
Weight and leptin changes among risperidone-treated youths with autism: 6-month prospective data.
|
Am J Psychiatry
|
2004
|
1.16
|
|
26
|
Moderators, mediators, and other predictors of risperidone response in children with autistic disorder and irritability.
|
J Child Adolesc Psychopharmacol
|
2010
|
1.15
|
|
27
|
Guanfacine treatment of hyperactivity and inattention in pervasive developmental disorders: a retrospective analysis of 80 cases.
|
J Child Adolesc Psychopharmacol
|
2004
|
1.15
|
|
28
|
Pharmacotherapy to control behavioral symptoms in children with autism.
|
Expert Opin Pharmacother
|
2012
|
1.12
|
|
29
|
Developing drugs for core social and communication impairment in autism.
|
Child Adolesc Psychiatr Clin N Am
|
2008
|
1.10
|
|
30
|
Aripiprazole for maladaptive behavior in pervasive developmental disorders.
|
J Child Adolesc Psychopharmacol
|
2004
|
1.09
|
|
31
|
Synergistic action of 5-HT2A antagonists and selective serotonin reuptake inhibitors in neuropsychiatric disorders.
|
Neuropsychopharmacology
|
2002
|
1.08
|
|
32
|
High blood monocyte counts and neopterin levels in children with autistic disorder.
|
Am J Psychiatry
|
2003
|
1.07
|
|
33
|
Maternal folic acid supplementation and risk of autism.
|
JAMA
|
2013
|
1.07
|
|
34
|
Pharmacologic treatment of autism and related disorders.
|
Pediatr Ann
|
2007
|
1.07
|
|
35
|
Aripiprazole in pervasive developmental disorder not otherwise specified and Asperger's disorder: a 14-week, prospective, open-label study.
|
J Child Adolesc Psychopharmacol
|
2009
|
1.06
|
|
36
|
Antipsychotics in the treatment of autism.
|
J Clin Invest
|
2008
|
1.06
|
|
37
|
The amygdala and related structures in the pathophysiology of autism.
|
Pharmacol Biochem Behav
|
2002
|
1.05
|
|
38
|
Effects of risperidone and parent training on adaptive functioning in children with pervasive developmental disorders and serious behavioral problems.
|
J Am Acad Child Adolesc Psychiatry
|
2011
|
1.05
|
|
39
|
Open-label memantine in fragile X syndrome.
|
J Autism Dev Disord
|
2009
|
1.04
|
|
40
|
The use of selective serotonin reuptake inhibitors in autism and related disorders.
|
J Child Adolesc Psychopharmacol
|
2006
|
1.04
|
|
41
|
Pharmacologic treatment of behavioral symptoms associated with autism and other pervasive developmental disorders.
|
Curr Treat Options Neurol
|
2010
|
1.02
|
|
42
|
Exploring the manifestations of anxiety in children with autism spectrum disorders.
|
J Autism Dev Disord
|
2013
|
1.02
|
|
43
|
Open-label atomoxetine for attention-deficit/ hyperactivity disorder symptoms associated with high-functioning pervasive developmental disorders.
|
J Child Adolesc Psychopharmacol
|
2006
|
1.02
|
|
44
|
Positive effects of methylphenidate on inattention and hyperactivity in pervasive developmental disorders: an analysis of secondary measures.
|
Biol Psychiatry
|
2007
|
1.00
|
|
45
|
Gastrointestinal factors in autistic disorder: a critical review.
|
J Autism Dev Disord
|
2005
|
1.00
|
|
46
|
Serotoninergic mechanisms in the treatment of obsessive-compulsive disorder.
|
Drug Discov Today
|
2008
|
1.00
|
|
47
|
Brief report: autistic disorder in three children with cytomegalovirus infection.
|
J Autism Dev Disord
|
2004
|
0.99
|
|
48
|
Brief report: acamprosate in fragile X syndrome.
|
J Autism Dev Disord
|
2010
|
0.99
|
|
49
|
Body mass index change in autism spectrum disorders: comparison of treatment with risperidone and aripiprazole.
|
J Child Adolesc Psychopharmacol
|
2014
|
0.99
|
|
50
|
Brief Report: social disability in autism spectrum disorder: results from Research Units on Pediatric Psychopharmacology (RUPP) Autism Network trials.
|
J Autism Dev Disord
|
2013
|
0.98
|
|
51
|
Multidisciplinary assessment and treatment of self-injurious behavior in autism spectrum disorder and intellectual disability: integration of psychological and biological theory and approach.
|
J Autism Dev Disord
|
2015
|
0.97
|
|
52
|
Trial design challenges when combining medication and parent training in children with pervasive developmental disorders.
|
J Autism Dev Disord
|
2008
|
0.96
|
|
53
|
Changes in the diagnostic criteria for autism in DSM-5: controversies and concerns.
|
J Clin Psychiatry
|
2013
|
0.95
|
|
54
|
A prospective open trial of guanfacine in children with pervasive developmental disorders.
|
J Child Adolesc Psychopharmacol
|
2006
|
0.94
|
|
55
|
Examination of aggression and self-injury in children with autism spectrum disorders and serious behavioral problems.
|
Child Adolesc Psychiatr Clin N Am
|
2014
|
0.94
|
|
56
|
Positive effects of methylphenidate on social communication and self-regulation in children with pervasive developmental disorders and hyperactivity.
|
J Autism Dev Disord
|
2008
|
0.94
|
|
57
|
Aripiprazole in autism spectrum disorders and fragile X syndrome.
|
Neurotherapeutics
|
2010
|
0.92
|
|
58
|
Pharmacological strategies for trichotillomania.
|
Expert Opin Pharmacother
|
2005
|
0.92
|
|
59
|
From anxiety to autism: spectrum of abnormal social behaviors modeled by progressive disruption of inhibitory neuronal function in the basolateral amygdala in Wistar rats.
|
Psychopharmacology (Berl)
|
2007
|
0.92
|
|
60
|
Impact of acamprosate on behavior and brain-derived neurotrophic factor: an open-label study in youth with fragile X syndrome.
|
Psychopharmacology (Berl)
|
2013
|
0.92
|
|
61
|
Open-label riluzole in fragile X syndrome.
|
Brain Res
|
2010
|
0.91
|
|
62
|
A prospective open-label study of aripiprazole in fragile X syndrome.
|
Psychopharmacology (Berl)
|
2011
|
0.90
|
|
63
|
Increased cerebrospinal fluid corticotropin-releasing factor concentrations during tryptophan depletion in healthy adults.
|
Biol Psychiatry
|
2004
|
0.90
|
|
64
|
Research Units of Pediatric Psychopharmacology (RUPP) autism network randomized clinical trial of parent training and medication: one-year follow-up.
|
J Am Acad Child Adolesc Psychiatry
|
2012
|
0.90
|
|
65
|
Research knowledge among parents of children participating in a randomized clinical trial.
|
J Am Acad Child Adolesc Psychiatry
|
2005
|
0.89
|
|
66
|
Dietary status and impact of risperidone on nutritional balance in children with autism: a pilot study.
|
J Intellect Dev Disabil
|
2006
|
0.89
|
|
67
|
Sensory symptoms in autism spectrum disorders.
|
Harv Rev Psychiatry
|
2014
|
0.87
|
|
68
|
A double-blind, placebo-controlled trial of oral human immunoglobulin for gastrointestinal dysfunction in children with autistic disorder.
|
J Autism Dev Disord
|
2009
|
0.87
|
|
69
|
Brief report: bone fractures in children and adults with autism spectrum disorders.
|
J Autism Dev Disord
|
2015
|
0.87
|
|
70
|
Developmental disabilities modification of the Children's Global Assessment Scale.
|
Biol Psychiatry
|
2007
|
0.86
|
|
71
|
Pharmacologic treatments for the behavioral symptoms associated with autism spectrum disorders across the lifespan.
|
Dialogues Clin Neurosci
|
2012
|
0.86
|
|
72
|
Psychopharmacological interventions in autism spectrum disorder.
|
Harv Rev Psychiatry
|
2014
|
0.86
|
|
73
|
Cognitive effects of risperidone in children with autism and irritable behavior.
|
J Child Adolesc Psychopharmacol
|
2008
|
0.86
|
|
74
|
Guanfacine and guanfacine extended release: treatment for ADHD and related disorders.
|
CNS Drug Rev
|
2007
|
0.86
|
|
75
|
IQSEC2 and X-linked syndromal intellectual disability.
|
Psychiatr Genet
|
2016
|
0.85
|
|
76
|
A retrospective analysis of quetiapine in the treatment of pervasive developmental disorders.
|
J Clin Psychiatry
|
2004
|
0.84
|
|
77
|
Paliperidone for irritability in autistic disorder.
|
J Child Adolesc Psychopharmacol
|
2010
|
0.84
|
|
78
|
Mentorship of clinical-track junior faculty: impact of a facilitated peer-mentoring program to promote scholarly productivity.
|
Acad Psychiatry
|
2013
|
0.84
|
|
79
|
Predictors and moderators of parent training efficacy in a sample of children with autism spectrum disorders and serious behavioral problems.
|
J Autism Dev Disord
|
2012
|
0.83
|
|
80
|
Paliperidone for irritability in adolescents and young adults with autistic disorder.
|
Psychopharmacology (Berl)
|
2012
|
0.83
|
|
81
|
Standardised Observation Analogue Procedure (SOAP) for assessing parent and child behaviours in clinical trials.
|
J Intellect Dev Disabil
|
2009
|
0.83
|
|
82
|
Possible influence of variant of the P-glycoprotein gene (MDR1/ABCB1) on clinical response to guanfacine in children with pervasive developmental disorders and hyperactivity.
|
J Child Adolesc Psychopharmacol
|
2010
|
0.83
|
|
83
|
Intramuscular ziprasidone for acute agitation in adolescents.
|
J Child Adolesc Psychopharmacol
|
2004
|
0.83
|
|
84
|
Paliperidone palmitate in a child with autistic disorder.
|
J Child Adolesc Psychopharmacol
|
2011
|
0.82
|
|
85
|
An open-label naturalistic pilot study of acamprosate in youth with autistic disorder.
|
J Child Adolesc Psychopharmacol
|
2011
|
0.82
|
|
86
|
Pharmacotherapy of irritability in pervasive developmental disorders.
|
Child Adolesc Psychiatr Clin N Am
|
2008
|
0.81
|
|
87
|
Risperidone in pervasive developmental disorders.
|
Expert Rev Neurother
|
2005
|
0.81
|
|
88
|
Aripiprazole for irritability associated with autistic disorder in children and adolescents aged 6-17 years.
|
Ped Health
|
2010
|
0.81
|
|
89
|
Risperidone-related improvement of irritability in children with autism is not associated with changes in serum of epidermal growth factor and interleukin-13.
|
J Child Adolesc Psychopharmacol
|
2011
|
0.80
|
|
90
|
Double-blind, placebo-controlled, pilot trial of paliperidone augmentation in serotonin reuptake inhibitor-resistant obsessive-compulsive disorder.
|
J Clin Psychiatry
|
2013
|
0.79
|
|
91
|
Recent advances in the pharmacotherapy of autism.
|
Expert Rev Neurother
|
2002
|
0.79
|
|
92
|
Use of a Direct Observational Measure in a Trial of Risperidone and Parent Training in Children with Pervasive Developmental Disorders.
|
J Dev Phys Disabil
|
2013
|
0.79
|
|
93
|
Pharmacological augmentation strategies for treatment-resistant obsessive-compulsive disorder.
|
Expert Opin Pharmacother
|
2004
|
0.78
|
|
94
|
The effects of aripiprazole on electrocardiography in children with pervasive developmental disorders.
|
J Child Adolesc Psychopharmacol
|
2012
|
0.78
|
|
95
|
Ziprasidone treatment of two adolescents with psychosis.
|
J Child Adolesc Psychopharmacol
|
2004
|
0.78
|
|
96
|
Cerebrospinal fluid interleukin-6 in obsessive-compulsive disorder and trichotillomania.
|
Psychiatry Res
|
2002
|
0.78
|
|
97
|
Riluzole in autistic disorder.
|
J Child Adolesc Psychopharmacol
|
2011
|
0.78
|
|
98
|
Brief report: Pilot single-blind placebo lead-in study of acamprosate in youth with autistic disorder.
|
J Autism Dev Disord
|
2014
|
0.78
|
|
99
|
Special issue on autism spectrum disorders. Introduction.
|
Harv Rev Psychiatry
|
2014
|
0.78
|
|
100
|
Psychotherapy and medication management strategies for obsessive-compulsive disorder.
|
Neuropsychiatr Dis Treat
|
2011
|
0.78
|
|
101
|
Sounding a wake-up call: improving the lives of adults with autism.
|
J Am Acad Child Adolesc Psychiatry
|
2013
|
0.77
|
|
102
|
Ramelteon for insomnia in two youths with autistic disorder.
|
J Child Adolesc Psychopharmacol
|
2006
|
0.77
|
|
103
|
Iron homeostasis during risperidone treatment in children and adolescents.
|
J Clin Psychiatry
|
2015
|
0.77
|
|
104
|
Emerging drugs for the treatment of symptoms associated with autism spectrum disorders.
|
Expert Opin Emerg Drugs
|
2010
|
0.77
|
|
105
|
Case report: 16-Year-old male with autistic disorder with preoccupation with female feet.
|
J Autism Dev Disord
|
2012
|
0.77
|
|
106
|
Co-morbid intellectual disability and borderline personality disorder: a case series.
|
Psychiatry
|
2010
|
0.77
|
|
107
|
Risperidone: a potential treatment for autism.
|
Curr Opin Investig Drugs
|
2002
|
0.76
|
|
108
|
Memantine for comorbid obsessive-compulsive disorder and Asperger disorder suggests a link in glutamatergic dysregulation.
|
J Clin Psychopharmacol
|
2011
|
0.76
|
|
109
|
Priapism associated with trazodone in an adolescent with autism.
|
J Am Acad Child Adolesc Psychiatry
|
2002
|
0.75
|
|
110
|
Guanfacine extended release in two patients with pervasive developmental disorders.
|
J Child Adolesc Psychopharmacol
|
2011
|
0.75
|
|
111
|
Neural targets in the study and treatment of social cognition in autism spectrum disorder.
|
Handb Exp Pharmacol
|
2015
|
0.75
|
|
112
|
Treating autism spectrum disorders. Preface.
|
Child Adolesc Psychiatr Clin N Am
|
2008
|
0.75
|
|
113
|
Pharmacological management of agitation and aggression in an adolescent with autism.
|
J Am Acad Child Adolesc Psychiatry
|
2005
|
0.75
|
|
114
|
Investigation of TSPO variants in schizophrenia and antipsychotic treatment outcomes.
|
Pharmacogenomics
|
2015
|
0.75
|
|
115
|
Obsessive-compulsive disorder (OCD).
|
J Autism Dev Disord
|
2005
|
0.75
|
|
116
|
Pediatric psychopharmacology: mood, anxiety and disruptive behavior/pervasive developmental disorders.
|
Psychopharmacology (Berl)
|
2007
|
0.75
|
|
117
|
Assessment of the integrity of study blindness in a pediatric clinical trial of risperidone.
|
J Clin Psychopharmacol
|
2005
|
0.75
|
|
118
|
Beware of over-interpreting negative trials.
|
J Autism Dev Disord
|
2008
|
0.75
|
|
119
|
Acute onset of obsessive-compulsive disorder in an adolescent with acute lymphoblastic leukemia.
|
Psychosomatics
|
2005
|
0.75
|
|
120
|
Methylphenidate an effective treatment for ADHD?
|
J Autism Dev Disord
|
2004
|
0.75
|
|
121
|
Topiramate for weight loss in two young adult women with autism spectrum disorder.
|
J Child Adolesc Psychopharmacol
|
2015
|
0.75
|
|
122
|
It is time to take a stand for medical research and against terrorism targeting medical scientists.
|
Biol Psychiatry
|
2008
|
0.75
|
|
123
|
Psychopharmacologic treatment of children prenatally exposed to drugs of abuse.
|
Hum Psychopharmacol
|
2015
|
0.75
|
|
124
|
Buspirone for bruxism in a child with pervasive developmental disorder-not otherwise specified.
|
J Child Adolesc Psychopharmacol
|
2011
|
0.75
|
|
125
|
Acute tryptophan depletion in schizophrenic patients treated with clozapine.
|
Arch Gen Psychiatry
|
2002
|
0.75
|